Table 2.
Summary of key efficacy results
| Cohorts by PD-L1 expression | All patients (n = 146) | ||||||
|---|---|---|---|---|---|---|---|
| < 1% (n = 74) | ≥ 1–< 25% (n = 31) | ≥ 25–< 50% (n = 11) | ≥ 50% | ||||
| Total (n = 30) | EGFR − (n = 25) | EGFR + (n = 5) | |||||
| Best overall response, n (%) | |||||||
| PR | 9 (12.2) | 6 (19.4) | 4 (36.4) | 7 (23.3) | 7 (28.0) | 0 | 26 (17.8) |
| SD | 24 (32.4) | 10 (32.3) | 5 (45.5) | 12 (40.0) | 10 (40.0) | 2 (40.0) | 51 (34.9) |
| PD | 33 (44.6) | 13 (41.9) | 1 (9.1) | 7 (23.3) | 6 (24.0) | 1 (20.0) | 54 (37.0) |
| NE | 8 (10.8) | 2 (6.5) | 1 (9.1) | 4 (13.3) | 2 (8.0) | 2 (40.0) | 15 (10.3) |
| Objective response rate, % (95% CI) | 12.2 (5.7–21.8) | 19.4 (7.5–37.5) | 36.4 (10.9–69.2) | 23.3 (9.9–42.3) | 28.0 (12.1–49.4) | 0 | 17.8 (12.0–25.0) |
| Disease control rate, % (95% CI) | 44.6 (33.0–56.6) | 51.6 (33.1–69.8) | 81.8 (48.2–97.7) | 63.3 (43.9–80.1) | 68.0 (46.5–85.1) | 40.0 (5.3–85.3) | 52.7 (44.3–61.1) |
| Duration of response, months (95% CI) | 8.3 (3.8–22.3) | 27.1 (5.6–NE) | NR (2.8–NE) | 15.1 (2.8–NE) | 15.1 (2.8–NE) | NR | 13.6 (5.6–22.6) |
PR partial response, SD stable disease, PD progressive disease, NE not estimable, NR not reached